Related Experiment Videos

Mouse erythrocyte carriers osmotically loaded with methotrexate

Insights

Red blood cells (RBCs) can be loaded with methotrexate (MTX) using advanced techniques. MTX-loaded RBC ghosts (RBCGs) show potential for treating hepatoma ascites tumors in mice, increasing survival rates.

Area of Science:

  • Biomedical Engineering
  • Drug Delivery Systems
  • Oncology

Background:

  • Red blood cells (RBCs) and their ghosts (RBCGs) are explored as potential carriers for chemotherapy drugs.
  • Methotrexate (MTX) is an anticancer agent with challenges in targeted delivery and efficacy.

Purpose of the Study:

  • To investigate the optimization of MTX loading into RBCGs using active loading techniques.
  • To evaluate the stability, morphology, and in vivo efficacy of MTX-loaded RBCGs.

Main Methods:

  • Utilized slow dialysis and preswell methods for active MTX loading into RBCGs.
  • Investigated the impact of buffer compounds (ATP content, osmolarity) on MTX incorporation, leakage, and RBCG morphology.
  • Assessed the in vivo fate of MTX-loaded RBCGs and their therapeutic effect in a murine hepatoma ascites tumor model.

Main Results:

  • Active loading techniques increased MTX entrapment in RBCGs by up to 15-fold compared to simple incubation.
  • Buffer composition critically influenced MTX incorporation, retention, and RBCG structural integrity.
  • In vivo studies showed rapid clearance of MTX-loaded RBCGs by the reticuloendothelial system.
  • MTX-loaded RBCGs significantly increased the average survival time of tumor-bearing mice by 28.5-42.8%.

Conclusions:

  • Optimized loading methods enhance MTX encapsulation in RBCGs.
  • RBCGs serve as effective carriers for MTX delivery, demonstrating significant therapeutic potential against hepatoma ascites tumors.
  • Further research into RBCG-based drug delivery systems is warranted for cancer treatment.

Related Concept Videos